Human papillomavirus (HPV) vaccination is a cornerstone of cervical cancer prevention, particularly in low- and middle-income countries (LMICs), where the burden of disease remains high1. The World Health Organization (WHO) HPV Vaccine Introduction Clearing House reported that 147 countries (of 194 reporting) had fully introduced the HPV vaccine into their national schedules as of 20242. […]
Region: Global
Accelerating and broadening multisectoral partnerships for introducing and rebuilding HPV vaccination programmes
In this commentary, Sidibe and colleagues propose a conceptual framework to guide countries in identifying and engaging stakeholders for HPV vaccine implementation. The framework organises actors into three tiers—key players, close supporters, and influencers—enabling systematic mapping across Ministries of Health and Education, civil society, professional associations, media, and the private sector. Drawing on experiences from […]
Overview of CHIC symposia series: Summary of Africa and South Asia symposia
In this overview, Bolio and colleagues summarize the key challenges and lessons learned from the CHIC Africa (Addis Ababa, 2022) and South Asia (New Delhi, 2022) symposia, involving participants from 19 African and 7 South Asian countries. Topics covered include health information systems, Gavi applications, planning, stakeholder engagement, delivery platforms, and single-dose vaccination. The article […]
CHIC: Coalition to Strengthen the HPV Immunization Community – Briefing on HPV and Vaccination
This CHIC briefing document provides a concise overview of HPV disease burden, vaccination programmes, and key challenges facing low- and middle-income countries. It describes HPV as the most common sexually transmitted infection globally, responsible for over 630,000 new cancer cases and 311,000 deaths annually, with 530,000 being cervical cancers. The brief highlights that over 85% […]
Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue
In this introduction to the special issue, Borda and colleagues present an overview of the current global epidemiology of cervical cancer incidence and mortality, with the highest burden concentrated in Africa and Asia. The article highlights decreased HPV vaccination coverage in recent years and underlines the need for new vaccine introductions and programme strengthening to […]
Déclaration de consensus du Conseil de CHIC sur le VPH
Dans cette déclaration de consensus datée du 28 avril 2022, le Conseil HPV du CHIC accueille favorablement la conclusion du SAGE de l’OMS selon laquelle un vaccin anti-papillomavirus à dose unique confère une protection solide, comparable à un schéma à deux ou trois doses, et appelle les programmes nationaux de vaccination et les organes consultatifs […]
CHIC HPV Council Consensus Statement on One-Dose Recommendation
In this consensus statement dated April 28, 2022, the CHIC HPV Council welcomes the WHO SAGE conclusion that a single-dose HPV vaccine delivers solid protection comparable to two- or three-dose schedules, and urges national immunization programmes and policy bodies to act on this recommendation. The Council highlights benefits for girls and families (comparable protection), programme […]
Evidence for an HPV one-dose schedule
In this review, Stanley and colleagues examine the biological plausibility and clinical trial evidence supporting a single-dose HPV vaccination schedule. The authors synthesize data from randomized controlled trials—including KEN SHE (Kenya), DoRIS (Tanzania), the Costa Rica Vaccine Trial, and the IARC India trial—demonstrating high and durable efficacy comparable to multi-dose regimens. Post-licensure observational studies and […]
Routine HPV vaccination: Reflection on delivery strategies based on countries’ experiences
In this commentary, Waheed and colleagues reflect on HPV vaccine delivery strategies across several low- and middle-income countries, comparing country experiences against existing WHO guidelines. Three delivery approaches are documented: routinized campaign-mode vaccination using schools as the primary site (The Gambia, Zambia, Ethiopia), routine health facility services complemented by community and school outreach (Tanzania, Kenya, […]
Aspects financiers et/ou durabilité dans le contexte de l’élargissement de la population cible pour la vaccination – Discussion: questions-réponses
Les échanges ont porté sur la structure tarifaire différenciée des vaccins HPV : il a été précisé que les pays éligibles à GAVI peuvent accéder aux prix GAVI même pour des populations cibles élargies, et que les achats via l’UNICEF constituent une forme indirecte d’approvisionnement groupé bénéficiant notamment aux pays à faibles volumes. Sur la […]